Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pegylated CD25/CD122-selective interleukin-2 mutein STK-012

A pegylated, engineered variant form of the human cytokine interleukin 2 (IL-2; IL2), with selective binding affinity for IL-2 receptor subunit alpha (IL-2Ralpha; CD25) and beta (IL-2Rbeta; CD122), with potential immunoregulatory and antineoplastic activities. Upon administration, pegylated CD25/CD122-selective IL-2 mutein STK-012 targets and binds to CD25 and CD122 on antigen-activated effector T cells and activates CD25/CD122-mediated signaling. This activates cytotoxic T lymphocytes (CTLs), enhances T-cell-mediated tumor cell killing and decreases tumor cell proliferation. STK-012 does not activate peripheral natural killer (NK) and naive T cells, thereby circumventing the exacerbation of vascular leak syndrome (VLS) and other NK cell-mediated adverse effects associated with recombinant IL-2. CD25 and CD122 are highly expressed in antigen-activated and tumor-specific T cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:IL-2 partial agonist STK-012
interleukin-2 partial agonist STK-012
pegylated alpha/beta-biased engineered interleukin-2 STK-012
pegylated alpha/beta-selective IL-2 mutein STK-012
pegylated CD25/CD122-selective IL-2 mutein STK-012
Code name:STK 012
STK-012
STK012
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search